{"id":"NCT01160380","sponsor":"Oncotherapeutics","briefTitle":"A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma","officialTitle":"A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2013-06","completion":"2014-05","firstPosted":"2010-07-12","resultsPosted":"2014-11-06","lastUpdate":"2014-11-06"},"enrollment":50,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Fatigue","Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"armodafinil","otherNames":["Nuvigil"]},{"type":"DRUG","name":"Placebo","otherNames":["sugar-pill"]}],"arms":[{"label":"Armodafinil","type":"EXPERIMENTAL"},{"label":"Placebo-First","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy of armodafinil for the treatment of cancer-related fatigue in adult patients with multiple myeloma. The study consists of a screening period, followed by a 56-day treatment phase, and a final assessment to occur 28 days after the end of the last treatment.","primaryOutcome":{"measure":"BFI Score","timeFrame":"Day 1, Day 28 and Day 56","effectByArm":[{"arm":"Armodafinil","deltaMin":65,"sd":13.2},{"arm":"Placebo-First","deltaMin":57.2,"sd":14.3}],"pValues":[{"comp":"OG000 vs OG001","p":"0.289"},{"comp":"OG001","p":"<0.001"},{"comp":"OG000","p":"<0.002"},{"comp":"OG000","p":"0.449"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":14},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":50},"commonTop":["G3/G4 Lymphopenia","G3/G4 Leukopenia","G3/G4 Neutropenia","G3/G4 BUN (increased)","G3/G4 Creatinine (increased)"]}}